RxDoctor Payments Data

Donald Martinelli, MD

Internal Medicine · Brooklyn, NYNPI 1710926001

Payments from drug & device makers

$1,541in general payments, 2019–2025

Across 31 payments — averaging $49.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$609
  • Novo Nordisk$142
  • Tandem Diabetes Care, Inc.$138
  • Phathom Pharmaceuticals, Inc.$130
  • Gilead$116
  • Sunovion Pharmaceuticals Inc.$110
  • plus $295 from 7 others

What the payments were for

  • Food & beverage$1,541100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,541 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$465,525
Medicare patients
363
Services billed
8,650

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban287$104,883
SantylCollagenase Clostridium Hist.199$70,171
Abilify MaintenaAripiprazole12$36,117
JanuviaSitagliptin Phosphate57$30,505
JardianceEmpagliflozin51$30,059
TradjentaLinagliptin63$21,043
XareltoRivaroxaban23$14,739
TrulicityDulaglutide11$11,518
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr22$10,189
LinzessLinaclotide12$9,353
JanumetSitagliptin Phos/Metformin Hcl13$9,124
EntrestoSacubitril/Valsartan12$7,955
Diflorasone Diacetate13$7,463
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$7,432
Dexlansoprazole DrDexlansoprazole13$4,653

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$104,883287 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$49$36,11712 claims
Lilly USA, LLCTrulicity$12$11,51811 claims
GSKAnoro Ellipta$609$10,18922 claims
AstraZenecaSymbicort$31$3,92413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →